Agenus announced highly positive early Phase 2 results for its combination therapy BOT+BAL in dMMR colon cancer, showing a 72% pathological complete response rate. This strong efficacy data could significantly de-risk the therapy and boost investor confidence in Agenus's oncology pipeline.
Agenus reported compelling early Phase 2 results for its BOT+BAL combination therapy in dMMR colon cancer, with 72% of patients achieving no remaining cancer after treatment. This high pathological complete response rate is a significant positive signal, suggesting strong efficacy for a difficult-to-treat cancer. This news is a major catalyst for Agenus, potentially increasing its valuation and attracting further investment. In the short term, Agenus's stock is likely to see a positive reaction. Long-term, these results could pave the way for accelerated development and potential market entry, offering a new treatment option for dMMR colon cancer patients and solidifying Agenus's position in the immuno-oncology space. The key opportunity for traders is the potential for significant upside in AGEN shares.